IGHE and asthma: The present observational prospective cohort study shows a consistent association between the administration of Beltavac® allergen immunotherapy with polymerized HDM extract under a convenient subcutaneous once-a-month rush protocol and clinical improvements during the first year of immunotherapy in children diagnosed with IgE-mediated allergic rhinoconjunctivitis, with and without asthma, sensitized to HDM allergens.